A BILL 
To significantly lower prescription drug prices for patients 
in the United States by ending government-granted mo-
nopolies for manufacturers who charge drug prices that 
are higher than the median prices at which the drugs 
are available in other countries. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
05:25 May 20, 2021
H2148
2 
•HR 2148 IH
SECTION 1. SHORT TITLE. 
1
This Act may be cited as the ‘‘Prescription Drug 
2
Price Relief Act of 2021’’. 
3
SEC. 2. IDENTIFICATION OF EXCESSIVELY PRICED DRUGS. 
4
(a) IN GENERAL.—The Secretary, not later than 1 
5
year after the date of enactment of this Act, shall establish 
6
a process to conduct a review of all brand name drugs, 
7
not less frequently than once per calendar year, under 
8
which the Secretary determines under subsection (b) 
9
whether the price of each such drug is excessive. 
10
(b) EXCESSIVE PRICE DETERMINATIONS.— 
11
(1) INTERNATIONAL REFERENCE PRICE.— 
12
(A) IN GENERAL.—The Secretary shall de-
13
termine that any brand name drug for which 
14
the domestic average manufacturing price ex-
15
ceeds the median price charged for such drug in 
16
the 5 reference countries to have an excessive 
17
price. In assessing the extent to which the price 
18
is excessive, the Secretary shall consider the 
19
factors described in paragraph (2). 
20
(B) REFERENCE COUNTRIES.—In this Act, 
21
the term ‘‘reference countries’’ means Canada, 
22
the United Kingdom, Germany, France, and 
23
Japan. 
24
(C) REQUIREMENT
WITH
RESPECT
TO 
25
DRUGS FOR WHICH CERTAIN REFERENCE COUN-
26
05:25 May 20, 2021
H2148
3 
•HR 2148 IH
TRY
INFORMATION
IS
NOT
AVAILABLE.—The 
1
Secretary shall make a determination under 
2
paragraph (1) for every brand name drug for 
3
which pricing information is available for at 
4
least 3 of the 5 reference countries. 
5
(2) DETERMINATIONS BASED ON OTHER FAC-
6
TORS.—With respect to any brand name drug that 
7
is not determined to have an excessive price by oper-
8
ation of paragraph (1) (including any drug for which 
9
there is insufficient data to make such a determina-
10
tion under such paragraph), the Secretary shall de-
11
termine that such drug has an excessive price if the 
12
price of the drug is higher than reasonable taking 
13
into account the following factors: 
14
(A) The size of the affected patient popu-
15
lation. 
16
(B) The value of the drug to patients, in-
17
cluding the impact of the price on access to the 
18
drug and the relationship of the price of the 
19
drug to its therapeutic health benefits. 
20
(C) The risk adjusted value of Federal 
21
Government subsidies and investments related 
22
to the drug. 
23
(D) The costs associated with development 
24
of the drug. 
25
05:25 May 20, 2021
H2148
4 
•HR 2148 IH
(E) Whether the drug provided a signifi-
1
cant improvement in health outcomes, com-
2
pared to other therapies available at the time of 
3
its approval. 
4
(F) The cumulative global revenues gen-
5
erated by the drug. 
6
(G) Whether the domestic average manu-
7
facturer price of the drug increased during any 
8
annual quarter by a percentage that is more 
9
than the percentage increase in the consumer 
10
price index for all urban consumers for the re-
11
spective annual quarter. 
12
(H) Other factors the Secretary determines 
13
appropriate. 
14
(c) PETITION FOR DETERMINATION.— 
15
(1) IN GENERAL.—Any person may petition the 
16
Secretary, in accordance with section 553(e) of title 
17
5, United States Code, to make an excessive drug 
18
price determination for an applicable drug under 
19
subsection (b)(2). Not later than 90 days after the 
20
date of receipt of such a petition, subject to para-
21
graph (2), the Secretary shall— 
22
(A) make a determination under subsection 
23
(b)(2) regarding such drug; or 
24
05:25 May 20, 2021
H2148
5 
•HR 2148 IH
(B)(i) decline to make such a determina-
1
tion; and 
2
(ii) make public the reasons why the Sec-
3
retary has declined to make such a determina-
4
tion. 
5
(2) EXCEPTION.—The Secretary shall not make 
6
a determination under subsection (b)(2) for a drug 
7
in response to a petition under this section more fre-
8
quently than once per calendar year. 
9
(3) 
PUBLIC
AVAILABILITY.—The 
Secretary 
10
shall make any petitions submitted under this sub-
11
section, together with any documentation related to 
12
the petitions and the Secretary’s determinations on 
13
such petitions and rationale for such determinations, 
14
publicly available, including by posting such informa-
15
tion on the database under section 5. 
16
SEC. 3. ENDING GOVERNMENT-GRANTED MONOPOLIES FOR 
17
EXCESSIVELY PRICED DRUGS. 
18
(a) EXCESSIVE DRUG PRICE AUTHORITY.—With re-
19
spect to any brand name drug, if the Secretary determines 
20
under section 2 that the price of the drug is excessive, 
21
the Secretary— 
22
(1) shall waive or void any government-granted 
23
exclusivities with respect to such drug, effective on 
24
05:25 May 20, 2021
H2148
6 
•HR 2148 IH
the date that the excessive price determination under 
1
section 2 is made for such drug; and 
2
(2) shall grant open, non-exclusive licenses al-
3
lowing any person to make, use, offer to sell or sell, 
4
or import into the United States such drug, and to 
5
rely upon the regulatory test data of such drug, in 
6
accordance with section 4. 
7
(b) EXPEDITED
REVIEW.—The Secretary shall 
8
prioritize the review of, and act within 8 months of the 
9
date of the submission of a generic drug application or 
10
a biosimilar biological product application if such applica-
11
tion references a drug licensed under subsection (a)(2). 
12
(c) CIVIL ACTIONS.—If the Secretary determines that 
13
the manufacturer of an excessively priced drug (as deter-
14
mined under section 2(a)) has increased the price of such 
15
drug during the period beginning on the date on which 
16
such price determination is made and ending on the date 
17
on which an entity begins manufacturing the drug under 
18
an open, non-exclusive license under subsection (a)(2), the 
19
Secretary may file a civil action in the United States dis-
20
trict court for the district in which the manufacturer is 
21
located, or in the United States district court for the Dis-
22
trict of Columbia, to recover damages in an amount equal 
23
to not less than the total amount of revenue derived by 
24
the manufacturer as a result of any such price increase 
25
05:25 May 20, 2021
H2148
7 
•HR 2148 IH
during such period. In actions brought under this sub-
1
section, the district courts shall have jurisdiction to grant 
2
all appropriate relief including, but not limited to, injunc-
3
tive relief and compensatory damages. 
4
SEC. 4. EXCESSIVE DRUG PRICE LICENSE. 
5
(a) REASONABLE ROYALTY.— 
6
(1) IN GENERAL.—An entity accepting an open, 
7
non-exclusive license under section 3(a)(2) shall pay 
8
a reasonable royalty to the holder of a patent that 
9
claims the drug or that claims a use of the drug or 
10
to the holder of an application approved under sub-
11
section 505(c) of the Federal Food, Drug, and Cos-
12
metic Act or section 351(a) of the Public Health 
13
Service Act for which any government-granted exclu-
14
sivity with respect to the drug was terminated under 
15
section 5(a)(1). 
16
(2) ROYALTY RATE.—Such royalty rate shall 
17
be— 
18
(A) a percentage of sales, where the per-
19
centage rate is no higher than the average roy-
20
alty rate estimated from the data provided by 
21
the Internal Revenue Service for pharma-
22
ceutical manufacturer Federal income tax re-
23
turns; or 
24
05:25 May 20, 2021
H2148
8 
•HR 2148 IH
(B) an amount as determined by the Sec-
1
retary, taking into account— 
2
(i) the value of the drug to patients; 
3
(ii) the size of the affected patient 
4
population; 
5
(iii) the risk adjusted value of the 
6
Federal Government subsidies and invest-
7
ments related to the drug; 
8
(iv) whether the drug provided a sig-
9
nificant improvement in health outcomes, 
10
compared to other therapies available at 
11
the time of the approval; 
12
(v) the extent to which the brand 
13
name drug manufacturer has recovered 
14
risk adjusted investments related to the 
15
drug, including the investments related to 
16
the invention, regulatory test data and any 
17
other relevant research and development 
18
costs; and 
19
(vi) any other information the Sec-
20
retary determines appropriate. 
21
(b) REQUIREMENTS.— 
22
(1) IN GENERAL.—A royalty rate under sub-
23
section (a) shall be consistent with making drugs 
24
available to purchasers, including Federal, State, 
25
05:25 May 20, 2021
H2148
9 
•HR 2148 IH
local, and nongovernmental purchasers and individ-
1
uals, at prices that are affordable and reasonable. 
2
Under no condition shall a royalty be set at a rate 
3
that would cause a product for which an open, non- 
4
exclusive license was issued under section 3 to be 
5
sold at an excessive price, as determined under sec-
6
tion 2. 
7
(2) MULTIPLE
AFFECTED
PARTIES.—In the 
8
case that there is one or more holders or investors 
9
in the patented inventions related to the drug in ad-
10
dition to the brand name manufacturer, the royalty 
11
rate shall be divided among the holders or investors 
12
(including such manufacturer) in a manner agreed 
13
upon by the manufacturer and other holders or in-
14
vestors, or, in the absence of such an agreement, in 
15
a manner the Secretary determines to be appro-
16
priate. 
17
(3) PRICE.—An entity accepting an open, non- 
18
exclusive license under section 3(a)(2) shall sell the 
19
drug at a price not higher than the excessive price 
20
determined for that drug under section 2(b). 
21
SEC. 5. PUBLIC EXCESSIVE DRUG PRICE DATABASE. 
22
(a) EXCESSIVE DRUG PRICE DATABASE.— 
23
(1) IN GENERAL.—The Secretary shall establish 
24
and maintain a comprehensive, up-to-date database 
25
05:25 May 20, 2021
H2148
10 
•HR 2148 IH
of brand name drugs and the excessive price deter-
1
minations for such drugs under section 2. 
2
(2) CONTENTS.—The database shall include, at 
3
a minimum, for each brand name drug, for the ap-
4
plicable calendar year— 
5
(A) the name of the drug; 
6
(B) the manufacturer; 
7
(C) whether the drug was determined 
8
under section 2(b) to have an excessive price; 
9
(D) the number of petitions the Secretary 
10
received under section 2(c) to make an exces-
11
sive price determination for the drug, together 
12
with the information described in section 
13
2(c)(3); 
14
(E) the number of open, non-exclusive li-
15
censes the Secretary has granted under section 
16
3(a)(2) for generic drug or biosimilar biological 
17
product versions of the drug; and 
18
(F) the number of applications under sub-
19
section (b)(2) or (j) of section 505 of the Fed-
20
eral Food, Drug, and Cosmetic Act or under 
21
section 351(k) of the Public Health Service Act 
22
submitted to the Secretary, pursuant to such a 
23
license granted under section 3(a)(2), and the 
24
05:25 May 20, 2021
H2148
11 
•HR 2148 IH
number of such applications that have been ap-
1
proved. 
2
(3) CERTAIN DETERMINATIONS.—With respect 
3
to a determination made under section 2(b)(1), the 
4
Secretary shall publish on the database such deter-
5
mination in accordance with paragraph (1) within 
6
30 days of receiving domestic and international pric-
7
ing information from manufacturers under section 6. 
8
(b) ANNUAL REPORTS
TO CONGRESS.—Not later 
9
than 60 days after the first excessive price review under 
10
section 2 is complete, and annually thereafter, the Sec-
11
retary shall submit to Congress a report describing the 
12
excessive drug price review for the preceding year. The 
13
report shall contain summary data regarding— 
14
(1) the total number of drugs that were re-
15
viewed; 
16
(2) the total number of drugs determined to be 
17
excessively priced under each of paragraphs (1) and 
18
(2) of section 2(b), and the name and manufacturer 
19
of each such drug; 
20
(3) the total number of drugs determined to be 
21
excessively priced, listed by manufacturer; 
22
(4) the extent to which the prices of the drugs 
23
identified under section 2 were higher than reason-
24
able, on average; 
25
05:25 May 20, 2021
H2148
12 
•HR 2148 IH
(5) the total number of drugs for which an 
1
open-non-exclusive license has been granted under 
2
section 3(a)(2); 
3
(6) the total number of generic drug or bio-
4
similar biological product applications received and 
5
approved that reference a drug so licensed; 
6
(7) the median approval time for generic drug 
7
or biosimilar biological product applications that ref-
8
erence a drug so licensed; 
9
(8) the total number of petitions the Secretary 
10
received under section 2(c) to make excessive price 
11
determinations for drugs; 
12
(9) a list of any manufacturers who failed to re-
13
port information as required under section 6; and 
14
(10) other appropriate information, as the Sec-
15
retary determines or as Congress requests. 
16
(c) PUBLIC
AVAILABILITY.—The Secretary shall 
17
make the information in the database described in sub-
18
section (a) and the report in subsection (b) publicly avail-
19
able, including on the internet website of the Food and 
20
Drug Administration, in a manner that is easy to find and 
21
understand. 
22
SEC. 6. DRUG MANUFACTURER REPORTING. 
23
(a) IN GENERAL.—Each manufacturer shall submit 
24
to the Secretary, in such format as the Secretary may re-
25
05:25 May 20, 2021
H2148
13 
•HR 2148 IH
quire, an annual report that includes the following infor-
1
mation for each brand name drug of the manufacturer, 
2
with respect to the previous calendar year: 
3
(1) The average manufacturer price of the drug 
4
in the United States and in the reference countries, 
5
for the entire year, and broken down for each quar-
6
ter of the year. 
7
(2) The wholesale acquisition cost of the drug 
8
in the United States and in the reference countries, 
9
for the entire year, and broken down for each quar-
10
ter of the year. 
11
(3) Cumulative global revenues generated by 
12
the drug. 
13
(4) Annual net sales revenue generated by the 
14
drug in the United States and in the reference coun-
15
tries, for the entire year, and broken down for each 
16
quarter of the year. 
17
(5) Total expenditures on domestic and foreign 
18
drug research and development related to the drug, 
19
itemized by— 
20
(A) basic and preclinical research; 
21
(B) clinical research, reported separately 
22
for each clinical trial; 
23
05:25 May 20, 2021
H2148
14 
•HR 2148 IH
(C) development of alternative dosage 
1
forms and strengths for the drug molecule or 
2
combinations, including the molecule; 
3
(D) other drug development activities, such 
4
as nonclinical laboratory studies and record and 
5
report maintenance; 
6
(E) pursuing new or expanded indications 
7
for such drug through supplemental applica-
8
tions under section 505 of the Federal Food, 
9
Drug, and Cosmetic Act; and 
10
(F) carrying out postmarket requirements 
11
related to such drug, including under section 
12
505(o)(3) of the Federal Food, Drug, and Cos-
13
metic Act. 
14
(6) Total expenditures on domestic and foreign 
15
marketing and advertising related to the drug. 
16
(7) Investments in human clinical trials related 
17
to the drug, by each trial and each year, including 
18
grants, research contracts, tax credits or deductions, 
19
and reimbursements from public or private health 
20
plans or insurance, and any other public sector sub-
21
sidies or incentives, such as the fair market value or 
22
priority review vouchers or other considerations. 
23
(8) The estimated size of the affected patient 
24
population. 
25
05:25 May 20, 2021
H2148
15 
•HR 2148 IH
(9) Additional information the manufacturer 
1
chooses to provide related to drug pricing decisions, 
2
such as information related to the methodology used 
3
to set the price of the drug. 
4
(10) Additional information as the Secretary 
5
determines necessary to carry out this Act, including 
6
information for previous years. 
7
(b) REPORT DUE DATE.—Applicable manufacturers 
8
shall submit the reports described in subsection (a) not 
9
later than January 15 of the year following the date of 
10
enactment of this Act, and of each year thereafter. 
11
(c) PENALTY FOR NONCOMPLIANCE.— 
12
(1) IN GENERAL.—Any manufacturer that fails 
13
to submit information for a drug as required by this 
14
section on a timely basis or that knowingly provides 
15
false information shall be liable for a civil monetary 
16
penalty, as determined by the Secretary under para-
17
graph (2), in addition to any other penalty under 
18
other applicable provisions of law. 
19
(2) AMOUNT OF PENALTY.—The amount of a 
20
civil penalty under paragraph (1) shall be equal to 
21
the product of— 
22
(A) an amount, as determined appropriate 
23
by the Secretary, which is— 
24
05:25 May 20, 2021
H2148
16 
•HR 2148 IH
(i) not less than 0.5 percent of the 
1
gross revenues from sales for the previous 
2
calendar year of the drug for which the in-
3
formation was not submitted; and 
4
(ii) not greater than 1 percent of the 
5
gross revenues from sales for the previous 
6
calendar year of such drug; and 
7
(B) the number of days in the period be-
8
tween— 
9
(i) the report due date under sub-
10
section (b); and 
11
(ii) the date on which the Secretary 
12
receives the information required to be re-
13
ported by the manufacturer under this sec-
14
tion. 
15
(3) USE
OF
CIVIL
PENALTY.—The Secretary 
16
shall collect the civil penalties under this subsection 
17
and shall use such funds to support competitive re-
18
search grant programs of the National Institutes of 
19
Health. 
20
SEC. 7. PROHIBITION OF ANTICOMPETITIVE BEHAVIOR. 
21
No manufacturer may engage in anticompetitive be-
22
havior violating section 5(a) of the Federal Trade Com-
23
mission Act (15 U.S.C. 45(a)) with another manufacturer 
24
that may interfere with the issuance and implementation 
25
05:25 May 20, 2021
H2148
17 
•HR 2148 IH
of open, non-exclusive licenses under this Act or otherwise 
1
run contrary to the public interest in the availability of 
2
affordable prescription drugs. 
3
SEC. 8. DEFINITIONS. 
4
For the purposes of this Act: 
5
(1) AVERAGE MANUFACTURER PRICE.— 
6
(A) IN
GENERAL.—The term ‘‘average 
7
manufacturer price’’, with respect to a drug, 
8
subject to subparagraph (B), has the meaning 
9
given such term in section 1927(k)(1) of the 
10
Social Security Act (42 U.S.C. 1396r–8(k)(1)); 
11
or with respect to a drug for which there is no 
12
average manufacturer price as so defined, such 
13
term shall mean the wholesale acquisition cost 
14
(as defined in section 1847A(c)(6)(B) of the 
15
Social 
Security 
Act 
(42 
U.S.C. 
1395w– 
16
3a(c)(6)(B)) of the drug. 
17
(B) APPLICATION TO REFERENCE COUN-
18
TRIES.—With respect to reference countries, 
19
the term ‘‘average manufacturer price’’, as de-
20
fined in subparagraph (A), shall be determined 
21
based on the price of the drug in the applicable 
22
reference country. 
23
(2) BIOSIMILAR
BIOLOGICAL
PRODUCT.—The 
24
term ‘‘biosimilar biological product’’ means a biologi-
25
05:25 May 20, 2021
H2148
18 
•HR 2148 IH
cal product licensed pursuant to an application 
1
under section 351(k) of the Public Health Service 
2
Act (42 U.S.C. 262(k)). 
3
(3) BRAND
NAME
DRUG.—The term ‘‘brand 
4
name drug’’ means a drug that is— 
5
(A) approved under section 505(c) of the 
6
Federal Food, Drug, and Cosmetic Act (21 
7
U.S.C. 355(c)) or a biological product licensed 
8
under section 351(a) of the Public Health Serv-
9
ice Act (42 U.S.C. 262(a)); 
10
(B) subject to section 503(b)(1) of the 
11
Federal Food, Drug, and Cosmetic Act (21 
12
U.S.C. 353(b)(1)); and 
13
(C) claimed in a patent or the use of which 
14
is claimed in a patent. 
15
(4) GENERIC DRUG.—The term ‘‘generic drug’’ 
16
means a drug approved pursuant to an application 
17
under section (b)(2) or (j) of the Federal Food, 
18
Drug, and Cosmetic Act (21 U.S.C. 355). 
19
(5) GOVERNMENT-GRANTED
EXCLUSIVITY.— 
20
The term ‘‘government-granted exclusivity’’ means 
21
prohibitions on the submission or approval of drug 
22
applications granted under any of the following: 
23
05:25 May 20, 2021
H2148
19 
•HR 2148 IH
(A) Clauses (ii) through (v) of section 
1
505(c)(3)(E) of the Federal Food, Drug, and 
2
Cosmetic Act (21 U.S.C. 355(c)(3)(E)). 
3
(B) Section 505(j)(5)(B)(iv) of the Federal 
4
Food, Drug, and Cosmetic Act (21 U.S.C. 
5
355(j)(5)(B)(iv)) or clause (ii), (iii), or (iv) of 
6
section 505(j)(5)(F) of such Act. 
7
(C) Section 505A of the Federal Food, 
8
Drug, and Cosmetic Act (21 U.S.C. 355a). 
9
(D) Section 505E of the Federal Food, 
10
Drug, and Cosmetic Act (21 U.S.C. 355f). 
11
(E) Section 527 of the Federal Food, 
12
Drug, and Cosmetic Act (21 U.S.C. 360cc). 
13
(F) Section 351(k)(7) of the Public Health 
14
Service Act (42 U.S.C. 262(k)(7)). 
15
(G) Any other provision of law that pro-
16
vides for exclusivity (or extension of exclusivity) 
17
with respect to a drug. 
18
(6) MANUFACTURER.—The term ‘‘manufac-
19
turer’’ means the holder of an application approved 
20
under section 505 of the Federal Food, Drug, and 
21
Cosmetic Act (21 U.S.C. 355) or of a license issued 
22
under section 351 of the Public Health Service Act 
23
(42 U.S.C. 262). 
24
05:25 May 20, 2021
H2148
20 
•HR 2148 IH
(7) OPEN, 
NON-EXCLUSIVE
LICENSE.—The 
1
term ‘‘open, non-exclusive license’’ means a license 
2
that authorizes any person to use a patent held by 
3
a manufacturer that claims a brand name drug or 
4
a use of a brand name drug or rely upon regulatory 
5
test data for such drug, including patents held in 
6
common by the manufacturer and other entities, 
7
needed to produce, manufacture, import, export, dis-
8
tribute, offer in liquidation, sell, buy, or use such 
9
brand name drug. 
10
(8) SECRETARY.—The term ‘‘Secretary’’ means 
11
the Secretary of Health and Human Services. 
12
Æ 
05:25 May 20, 2021
H2148
